Vaccine rollouts, data and consultation

Question

2. What standards of evidence will the CDC require before supporting the rollout of a new vaccine? Would the CDC support vaccines that have undergone only limited-duration clinical trials, and what minimum follow-up period would it consider appropriate? 3. Will the CDC advocate for the public release of clinical trial data before the commencement of any vaccination programs? 4. Will the CDC recognise and uphold the principles of informed consent and bodily autonomy in all public health programs, including vaccination campaigns? 5. What systems will the CDC use to monitor vaccine safety in real time, and how will potential adverse events be identified, investigated and communicated to the public? 6. Will the CDC actively encourage healthcare professionals to report suspected adverse events associated with vaccines and other therapeutics? 7. Will the CDC require full disclosure of the composition and ingredients of vaccines supplied in Australia, notwithstanding claims of commercial confidentiality? 15. Will the CDC facilitate greater public access to clinical trial data and post-market surveillance data for vaccines and therapeutics? How will it support independent verification and replication of key findings? 21. What role does the CDC have in relation to vaccination schedules in Australia? 22. Will the CDC have any relationship with mRNA vaccine manufacturing facilities in Australia?

Answer

Please see attached answer.

Documents

• Question with answer (PDF) (opens in a new tab)
• ACDC SQ26-002838.pdf (opens in a new tab)